RNA test identifies large B-cell lymphoma subtypes: Lisa Rimsza, M.D.
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately define subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy for these cancers.
Speaker 2: (00:32)
Could you provide a brief background about yourself?
Speaker 2: (01:12)
Would you give us an overview of the PM3CX test?
Speaker 2: (03:02)
Which patients should have this testing?
Speaker 2: (05:14)
Is this test qualitative and RNA?
Speaker 2: (06:35)
After determining if it's primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma, does the test identify the cell of origin?
Speaker 2: (08:09)
For patients diagnosed with diffuse large B-cell lymphoma, what are the treatment recommendations?
Speaker 2: (09:04)
Are there any other insights about this test that you'd like to share?